The board of directors of SSY Group Limited announced that the Group's Cinacalcet Hydrochloride has obtained the approval for registration from the National Medical Products Administration of China to become a bulk drug for the preparations on the market. Cinacalcet is mainly used for the treatment of secondary hyperparathyroidism, primary hyperparathyroidism and parathyroid carcinoma.